{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:12:44Z","timestamp":1771863164031,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13318-025-00968-x","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:11:19Z","timestamp":1762179079000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Predictive Pharmacokinetic Models to Optimize Infliximab Therapy in Pediatric Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-4960","authenticated-orcid":false,"given":"Paulo","family":"Caceres Guido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo Federico","family":"Taboada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Quinteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fabbrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"7\u20138","key":"968_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1345\/aph.10395","volume":"35","author":"MS Serrano","year":"2001","unstructured":"Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother. 2001;35(7\u20138):823\u20138. https:\/\/doi.org\/10.1345\/aph.10395.","journal-title":"Ann Pharmacother"},{"key":"968_CR2","doi-asserted-by":"publisher","unstructured":"Larrosa-Haro A, Abundis-Castro L, Contreras MB, Gallo, et\u00a0al. Epidemiologic trend of pediatric inflammatory bowel disease in Latin America: the Latin American Society for Pediatric Gastroenterology, Hepatology and Nutrition (LASPGHAN) Working Group. Rev Gastroenterol Mex Engl Ed. 2020. https:\/\/doi.org\/10.1016\/j.rgmx.2020.07.010","DOI":"10.1016\/j.rgmx.2020.07.010"},{"issue":"3","key":"968_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5223\/pghn.2022.25.3.218","volume":"25","author":"MS Arcucci","year":"2022","unstructured":"Arcucci MS, Contreras MB, Gallo J, et\u00a0al. Pediatric inflammatory bowel disease: a multicenter study of changing trends in Argentina over the past 30 years. Pediatr Gastroenterol Hepatol Nutr. 2022;25(3):218\u201327. https:\/\/doi.org\/10.5223\/pghn.2022.25.3.218.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"3","key":"968_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.anpede.2023.01.007","volume":"98","author":"B Rodr\u00edguez Azor","year":"2023","unstructured":"Rodr\u00edguez Azor B, Mart\u00edn-Masot R, Dayaldasani Khialani A, Fern\u00e1ndez-Mart\u00edn JM, Gallego Fern\u00e1ndez C, Navas-L\u00f3pez VM. Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn's disease. An Pediatr (Engl Ed). 2023;98(3):165\u201374. https:\/\/doi.org\/10.1016\/j.anpede.2023.01.007.","journal-title":"An Pediatr (Engl Ed)"},{"issue":"5","key":"968_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/archdischild-2023-325668","volume":"109","author":"JJ Ashton","year":"2024","unstructured":"Ashton JJ, Beattie RM. Inflammatory bowel disease: recent developments. Arch Dis Child. 2024;109(5):370\u20136. https:\/\/doi.org\/10.1136\/archdischild-2023-325668.","journal-title":"Arch Dis Child"},{"issue":"1","key":"968_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00384-024-04640-9","volume":"39","author":"D Long","year":"2024","unstructured":"Long D, Wang C, Huang Y, Mao C, Xu Y, Zhu Y. Changing epidemiology of inflammatory bowel disease in children and adolescents. Int J Colorectal Dis. 2024;39(1):73. https:\/\/doi.org\/10.1007\/s00384-024-04640-9.","journal-title":"Int J Colorectal Dis"},{"issue":"Supplement_2","key":"968_CR7","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","volume":"18","author":"B Caron","year":"2024","unstructured":"Caron B, Honap S, Peyrin-Biroulet L. Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies. J Crohns Colitis. 2024;18(Supplement_2):ii3\u201315. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae082.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"968_CR8","first-page":"226","volume":"48","author":"M Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez M, Ossa JC, Alliende F, et\u00a0al. Enfermedad Inflamatoria Intestinal en pediatr\u00eda (IBD): revision. Grupo de trabajo de la Sociedad Latinoamericana de Gastroenterolog\u00eda, Hepatolog\u00eda y Nutrici\u00f3n Pedi\u00e1trica (SLAGHNP). Acta Gastroenterol\u00f3gica Latinoamericana. 2018;48(3):226\u201341.","journal-title":"Acta Gastroenterol\u00f3gica Latinoamericana."},{"issue":"9","key":"968_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.dld.2008.02.042","volume":"40","author":"R Caprilli","year":"2008","unstructured":"Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn\u2019s disease. Dig Liver Dis. 2008;40(9):709\u201316. https:\/\/doi.org\/10.1016\/j.dld.2008.02.042.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"968_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11894-020-00773-3","volume":"22","author":"MA Conrad","year":"2020","unstructured":"Conrad MA, Kelsen JR. The treatment of pediatric inflammatory bowel disease with biologic therapies. Curr Gastroenterol Rep. 2020;22(8):36. https:\/\/doi.org\/10.1007\/s11894-020-00773-3.","journal-title":"Curr Gastroenterol Rep"},{"issue":"23","key":"968_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, et\u00a0al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375\u201384. https:\/\/doi.org\/10.1001\/jama.2021.21316.","journal-title":"JAMA"},{"issue":"3","key":"968_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","volume":"46","author":"D Alsoud","year":"2024","unstructured":"Alsoud D, Moes DJAR, Wang Z, et\u00a0al. Best practice for therapeutic drug monitoring of Infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2024;46(3):291\u2013308. https:\/\/doi.org\/10.1097\/FTD.0000000000001204.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"968_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.52787\/agl.v52i3.245","volume":"52","author":"A M\u00ednguez","year":"2022","unstructured":"M\u00ednguez A, Nos P. Medicina de precisi\u00f3n en la enfermedad inflamatoria intestinal. Acta Gastroenterol Latinoam. 2022;52(3):334\u201343. https:\/\/doi.org\/10.52787\/agl.v52i3.245.","journal-title":"Acta Gastroenterol Latinoam"},{"issue":"8","key":"968_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/psp4.12813","volume":"11","author":"W Kantasiripitak","year":"2022","unstructured":"Kantasiripitak W, Outtier A, Wicha SG, et\u00a0al. Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT Pharmacometrics Syst Pharmacol. 2022;11(8):1045\u201359. https:\/\/doi.org\/10.1002\/psp4.12813.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"968_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.gtc.2023.05.002","volume":"52","author":"A Nasr","year":"2023","unstructured":"Nasr A, Minar P. The role of therapeutic drug monitoring in children. Gastroenterol Clin North Am. 2023;52(3):549\u201363. https:\/\/doi.org\/10.1016\/j.gtc.2023.05.002.","journal-title":"Gastroenterol Clin North Am"},{"issue":"5","key":"968_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.gastrohep.2024.01.007","volume":"47","author":"F Rodr\u00edguez-Moranta","year":"2024","unstructured":"Rodr\u00edguez-Moranta F, Arg\u00fcelles-Arias F, Hinojosa Del Val J, et\u00a0al. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis. Gastroenterol Hepatol. 2024;47(5):522\u201352. https:\/\/doi.org\/10.1016\/j.gastrohep.2024.01.007.","journal-title":"Gastroenterol Hepatol"},{"issue":"7","key":"968_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17425255.2019.1630378","volume":"15","author":"R Franca","year":"2019","unstructured":"Franca R, Curci D, Lucaf\u00f2 M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol. 2019;15(7):527\u201339. https:\/\/doi.org\/10.1080\/17425255.2019.1630378.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"968_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.medcli.2023.02.006","volume":"160","author":"P Mart\u00edn-Garc\u00eda","year":"2023","unstructured":"Mart\u00edn-Garc\u00eda P, Alonso-Arroyo A, Catal\u00e1-L\u00f3pez F. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: a systematic review. Med Clin (Barc). 2023;160(11):501\u201316. https:\/\/doi.org\/10.1016\/j.medcli.2023.02.006.","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"968_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40262-024-01354-7","volume":"63","author":"NC Bevers","year":"2024","unstructured":"Bevers NC, Keizer RJ, Wong DR, et\u00a0al. Performance of eight Infliximab population pharmacokinetic models in a cohort of Dutch children with inflammatory bowel disease. Clin Pharmacokinet. 2024;63(4):529\u201338. https:\/\/doi.org\/10.1007\/s40262-024-01354-7.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"968_CR20","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/ibd\/izad272","volume":"30","author":"SR Fernandes","year":"2024","unstructured":"Fernandes SR, Bernardo S, Saraiva S, et\u00a0al. Proactive Infliximab monitoring improves the rates of transmural remission in Crohn\u2019s disease: a propensity score-matched analysis. Inflamm Bowel Dis. 2024;30(11):1974\u201382. https:\/\/doi.org\/10.1093\/ibd\/izad272.","journal-title":"Inflamm Bowel Dis"},{"key":"968_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae231","author":"R Porth","year":"2024","unstructured":"Porth R, Deyhim T, Geeganage G, et\u00a0al. Proactive therapeutic drug monitoring of ustekinumab is associated with increased drug persistence in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae231.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"968_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/jcm14030845","volume":"14","author":"KY Wang","year":"2025","unstructured":"Wang KY, Heikal OS, van Rheenen PF, Touw DJ, Bourgonje AR, Mian P. Clinical and biochemical factors associated with infliximab pharmacokinetics in paediatric patients with inflammatory bowel disease. J Clin Med. 2025;14(3):845. https:\/\/doi.org\/10.3390\/jcm14030845.","journal-title":"J Clin Med"},{"issue":"2","key":"968_CR23","doi-asserted-by":"publisher","first-page":"e70086","DOI":"10.1111\/cts.70086","volume":"18","author":"A Samuels","year":"2025","unstructured":"Samuels A, Irie K, Mizuno T, et\u00a0al. Integrating early response biomarkers in pharmacokinetic models: a novel method to individualize the initial infliximab dose in patients with Crohn\u2019s disease. Clin Transl Sci. 2025;18(2):e70086. https:\/\/doi.org\/10.1111\/cts.70086.","journal-title":"Clin Transl Sci"},{"issue":"7","key":"968_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.gastrohep.2022.10.019","volume":"46","author":"LS D\u00edaz","year":"2023","unstructured":"D\u00edaz LS, Naval\u00f3n CI, Esp\u00edn RG, Prado IN, Redondo LR. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023;46(7):504\u201311. https:\/\/doi.org\/10.1016\/j.gastrohep.2022.10.019.","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"968_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/ecco-jcc\/jjad009","volume":"17","author":"W Kantasiripitak","year":"2023","unstructured":"Kantasiripitak W, Wicha SG, Thomas D, et\u00a0al. A model-based tool for guiding Infliximab induction dosing to maximize long-term deep remission in children with inflammatory bowel diseases. J Crohns Colitis. 2023;17(6):896\u2013908. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad009.","journal-title":"J Crohns Colitis"},{"key":"968_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen PF, Aloi M, Assa A, et\u00a0al. The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa161.","journal-title":"J Crohns Colitis"},{"key":"968_CR27","unstructured":"Merative TM Micromedex\u00ae DRUGDEX\u00ae. Merative, Ann Arbor, Michigan, USA. https:\/\/www.micromedexsolutions.com. Accessed 5 May 2025"},{"issue":"7","key":"968_CR28","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.7717\/peerj-cs.623","volume":"5","author":"D Chicco","year":"2021","unstructured":"Chicco D, Warrens MJ, Jurman G. The coefficient of determination R-squared is more informative than SMAPE, MAE, MAPE, MSE and RMSE in regression analysis evaluation. PeerJ Comput Sci. 2021;5(7):e623.","journal-title":"PeerJ Comput Sci"},{"issue":"8","key":"968_CR29","doi-asserted-by":"publisher","first-page":"e0203361","DOI":"10.1371\/journal.pone.0203361","volume":"13","author":"J Deng","year":"2018","unstructured":"Deng J, Jhandey A, Zhu X, et\u00a0al. In silico drug absorption tract: an agent-based biomimetic model for human oral drug absorption. PLoS ONE. 2018;13(8):e0203361. https:\/\/doi.org\/10.1371\/journal.pone.0203361.","journal-title":"PLoS ONE"},{"key":"968_CR30","doi-asserted-by":"publisher","first-page":"104478","DOI":"10.1016\/j.phrs.2019.104478","volume":"149","author":"S Salvador-Mart\u00edn","year":"2019","unstructured":"Salvador-Mart\u00edn S, L\u00f3pez-Cauce B, Nu\u00f1ez O, et\u00a0al. Genetic predictors of long-term response and trough levels of infliximab in Crohn\u2019s disease. Pharmacol Res. 2019;149:104478. https:\/\/doi.org\/10.1016\/j.phrs.2019.104478.","journal-title":"Pharmacol Res"},{"key":"968_CR31","doi-asserted-by":"publisher","first-page":"1342477","DOI":"10.3389\/fimmu.2024.1342477","volume":"15","author":"EA Spencer","year":"2024","unstructured":"Spencer EA, Dubinsky MC, Kamm MA, et\u00a0al. Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-\u03b1. Front Immunol. 2024;15:1342477. https:\/\/doi.org\/10.3389\/fimmu.2024.1342477.","journal-title":"Front Immunol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00968-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00968-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00968-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:38:51Z","timestamp":1771861131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00968-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00968-x","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"2 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The submitted work was previously approved by the Institutional Review Board of the Hospital de Pediatr\u00eda Garrahan (\"Comit\u00e9 Revisor y de \u00c9tica en Investigaci\u00f3n\"): ID 1714.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"As this is a retrospective study in which data were anonymized and delinked from any potential patient identification, the IRB granted a waiver for the requirement of obtaining informed consent from the involved patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Same as above.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data analyzed in this study will be made available upon request, provided that the justification for the potential request is reasonably sound.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Paulo C\u00e1ceres Guido: formulating the research question, developing the overall study design, performing statistical analyses, interpreting results, writing the manuscript, reviewing and editing content, taking responsibility for the work\u2019s integrity. Guillermo Federico Taboada: collecting data, reviewing and editing content, interpreting results, approving the final version, taking responsibility for the work\u2019s integrity. Gisela Gruber: data generation, collecting data, reviewing and editing content, interpreting results, approving the final version, taking responsibility for the work\u2019s integrity. Franco Garc\u00eda: formulating the research question, collecting data, reviewing and editing content, approving the final version, taking responsibility for the work\u2019s integrity. Laura P\u00e9rez: data generation, reviewing and editing content, approving the final version, taking responsibility for the work\u2019s integrity. Fernanda Quinteros: data generation, reviewing and editing content, approving the final version, taking responsibility for the work\u2019s integrity. David Fabbrini: data generation, collecting data, reviewing and editing content, approving the final version, taking responsibility for the work\u2019s integrity. M\u00f3nica Contreras: formulating the research question, data generation, collecting data, interpreting results, reviewing and editing content, approving the final version, taking responsibility for the work\u2019s integrity.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}